Say goodbye to
the intermediate
risk "gray zone".

Myriad Oncology

Each step. Every patient. Exactly what you need.

Say goodbye to the intermediate risk “gray zone”.

Not all prostate cancer genomic tests are built for intermediate risk.
The Prolaris® Test is.

Because no prostate cancer patient deserves the “gray zone,” the Prolaris Test provides clear answers to help support treatment discussions with your intermediate-risk patients.

Did you know that the Prolaris Test outperforms all other biomarkers in identifying which patients are appropriate for active surveillance and those who may benefit from treatment?1,2

PROLARIS ACTIVE SURVEILLANCE THRESHOLD

ACTIVE SURVEILLANCE

Regular monitoring and testing per guideline recommendations

TREATMENT

RT +/- ADT or surgery per guideline recommendations

SPEAK WITH OUR TEAM ABOUT HOW THE PROLARIS TEST CAN HELP GUIDE YOUR DECISIONS​

Take the next step with Prolaris

Request information on how Prolaris is personalizing cancer care.



By submitting your personal information, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in the communication we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Notice.

Hidden Fields











Hidden test fields

Contact Information

When active surveillance is on the table, use the test built for it.

Why would you choose a test that isn’t validated in untreated patients? Only the Prolaris Test has an active surveillance threshold validated in untreated patients, making it uniquely suited to help guide initial treatment decisions.1

The Prolaris Test outperforms all other biomarkers in identifying the right patients for active surveillance.1,2

  • In a pivotal Prolaris validation study, no patients below the active surveillance threshold died from prostate cancer.1
  • In a recent study, patients recommended for active surveillance by the Prolaris Test were twice as likely to choose it and had 50% higher 3-year durability compared to those recommended for definitive treatment.2

Clear results. Real-world impact.​

The Prolaris Test doesn’t just inform—it changes treatment plans.

In real-world clinical studies, the Prolaris Test influenced treatment decision changes in up to 65% of cases—helping clinicians to shift between active surveillance and definitive treatment based on individual risk.4,5

Up to 65%

of patients tested with the Prolaris Test had a change in their treatment plan4,5

Faster results.
Smarter workflow.​

Myriad Oncology™ helps customize your ordering process to meet your practice’s unique needs. With a physician-driven, conditional ordering model, Prolaris testing can be initiated directly from the pathology lab—so you get critical results faster, right when treatment decisions are being made.​

The beauty of conditional ordering? You stay in control—you decide which patients to test, and Myriad builds a workflow to support that​.

Request information

Graphic showing why to streamline your process from basic ordering to streamlined ordering

More resources

References
  1. Lin DW, Crawford ED, Keane T, et al. Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. Urol Oncol. 2018;36(6):310.e7-310.e13.
  2. Hu JC, Tosoian JJ, Qi J, et al. Clinical Utility of Gene Expression Classifiers in Men With Newly Diagnosed Prostate Cancer. JCO Precis Oncol. 2018;2:PO.18.00163.
  3. Lenz L, Clegg W, Iliev D, et al. Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing. Prostate Cancer Prostatic Dis. 2025;28(2):427-434.
  4. Shore ND, Kella N, Moran B, et al. Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer. J Urol. 2016;195(3):612-618.
  5. Crawford ED, Scholz MC, Kar AJ, et al. Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry. Curr Med Res Opin. 2014;30(6):1025-1031.

Locations

United States
Europe
Japan